Protein targets of 80-100g daily are non-negotiable
Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, et al
Retatrutide is a triple-receptor agonist that activates GLP-1, GIP, and glucagon pathways simultaneously, making it the most potent injectable weight loss compound currently in advanced clinical development
The paper suggests initiating therapy at roughly 1025% of standard starting dose for type 2 diabetes or obesity, which for tirzepatide (approved starting dose 2.5 mg) would be roughly 250625 g, or 0.25 0.625 mg
The gastrointestinal side effects of GLP-1s, including nausea, vomiting, and diarrhea, may be a reason people dont complete treatment, the study notes
Always check current rules of racing commissions and FEI guidelines